Biosceptre International Ltd

BABRAHAM, CAMBRIDGE, X0 · Founded 2013 · CIK 0001675425 · Biotech · Private

Multiple-targeted universal CAR T cell system for cancer immunotherapy

biosceptre.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.0M
3 Form D · Jun 2017
112 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 2 same dayForm D · SEC$99,270
Private capital raised· 2 of 2 same dayForm D · SEC$671,674
Private capital raisedForm D · SEC$237,230
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2570Decoy Therapeutics, Inc.—$1.0M
2571NEW HORIZON BIOTECH INC——
2572AMPLION INC.—$1.0M
2573Biosceptre International Ltd—$1.0M
2574MATINAS BIOPHARMA, INC.—$1.0M
2575CURIS INC—$964K
2576SUMOCOR, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Paul AxonDirector
  • Jonathan CollinsDirector
  • Peter CurrieDirector · Executive Officer
  • Michael LovettDirector
  • Shaun McNultyExecutive Officer
  • Peter NewtonDirector
  • Andrew Walton-GreenDirector
  • Ronald WattsDirector
  • Gregory WinterDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.